What is Achieve Life Sciences' operating income?

Achieve Life Sciences' total operating income in 2025 was -$54.88 million, based on the following breakdown: Total Gross Profit: $0.00 Total Operating Expenses: $54.88 million

Achieve Life Sciences (ACHV) Financials

$6.50 +0.26 (+4.17%)

Closing price 04:00 PM Eastern

Extended Trading

$6.45 -0.05 (-0.75%)

As of 05:53 PM Eastern

Compare

Annual Income Statements for Achieve Life Sciences

This table shows Achieve Life Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-17	-1.23	-11	-13	-16	-15	-33	-42	-30	-40	-55
Consolidated Net Income / (Loss)	-17	-1.23	-11	-13	-16	-15	-33	-42	-30	-40	-55
Net Income / (Loss) Continuing Operations	-17	-1.23	-11	-13	-16	-15	-33	-42	-30	-40	-54
Total Pre-Tax Income	-17	-1.74	-14	-13	-16	-15	-33	-42	-30	-40	-55
Total Operating Income	-19	-1.71	-6.63	-13	-17	-15	-33	-41	-28	-40	-55
Total Gross Profit	18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	37	1.71	6.63	13	17	15	33	41	28	40	55
Selling, General & Admin Expense	12	1.43	3.53	6.95	6.85	7.87	9.13	11	11	16	32
Research & Development Expense	25	0.29	3.10	5.87	9.67	6.88	24	30	16	23	23
Total Other Income / (Expense), net	1.95	-0.02	-7.00	0.13	0.13	0.02	-0.06	-1.55	-2.04	-0.14	0.23
Interest Expense	-	-	-	-	-	0.00	0.00	1.79	2.85	2.46	0.82
Interest & Investment Income	0.12	-	0.02	0.17	0.17	0.07	0.02	0.20	0.83	2.36	1.50
Other Income / (Expense), net	1.83	-0.02	-7.02	-0.05	-0.04	-0.05	-0.08	0.04	-0.01	-0.03	-0.44
Other Gains / (Losses), net	-	-	-	-	0.13	-	-0.06	-	-	-	0.23
Basic Earnings per Share	($0.64)	($581.25)	($22.07)	($72.29)	($39.76)	($5.42)	($4.08)	($4.00)	($1.50)	($1.24)	($1.25)
Weighted Average Basic Shares Outstanding	26.15M	2.12K	479.44K	175.51K	412.32K	2.72M	8.12M	10.59M	19.83M	32.07M	43.59M
Diluted Earnings per Share	($0.64)	($581.25)	($22.07)	($72.29)	($39.76)	($5.42)	($4.08)	($4.00)	($1.50)	($1.24)	($1.25)
Weighted Average Diluted Shares Outstanding	26.15M	2.12K	479.44K	175.51K	412.32K	2.72M	8.12M	10.59M	19.83M	32.07M	43.59M
Weighted Average Basic & Diluted Shares Outstanding	26.15M	2.12K	479.44K	175.51K	412.32K	2.72M	8.12M	17.93M	34.25M	34.69M	53.24M

This table shows Achieve Life Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-7.11	-5.48	-6.49	-8.46	-13	-12	-13	-13	-14	-15	-10
Consolidated Net Income / (Loss)	-7.11	-5.48	-6.49	-8.46	-13	-12	-13	-13	-14	-15	-10
Net Income / (Loss) Continuing Operations	-7.11	-5.48	-6.49	-8.49	-13	-12	-13	-13	-14	-14	-10
Total Pre-Tax Income	-7.11	-5.48	-6.49	-8.46	-13	-12	-13	-13	-14	-15	-10
Total Operating Income	-6.57	-4.91	-6.03	-8.43	-12	-13	-13	-13	-15	-15	-10
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	6.57	4.91	6.03	8.43	12	13	13	13	15	15	10
Selling, General & Admin Expense	2.99	2.27	3.18	3.32	4.86	4.89	5.80	5.86	9.37	11	7.17
Research & Development Expense	3.58	2.11	2.80	5.11	7.61	7.30	7.10	6.71	5.32	3.87	3.29
Total Other Income / (Expense), net	-0.54	-0.56	-0.46	-0.03	-0.05	0.40	0.07	-0.06	0.36	-0.13	0.30
Interest Expense	0.78	0.79	0.81	0.80	0.65	0.20	0.19	0.19	0.19	0.25	0.27
Interest & Investment Income	0.26	0.21	0.37	0.83	0.67	0.48	0.32	0.19	0.55	0.43	0.30
Other Income / (Expense), net	-0.02	0.02	-0.02	-0.06	-0.07	0.11	-0.07	-0.06	-0.01	-0.31	0.27
Basic Earnings per Share	($0.34)	($0.23)	($0.26)	($0.25)	($0.36)	($0.37)	($0.37)	($0.37)	($0.28)	($0.23)	($0.19)
Weighted Average Basic Shares Outstanding	21.13M	19.83M	25.05M	34.32M	34.36M	32.07M	34.69M	34.69M	51.02M	43.59M	53.38M
Diluted Earnings per Share	($0.34)	($0.23)	($0.26)	($0.25)	($0.36)	($0.37)	($0.37)	($0.37)	($0.28)	($0.23)	($0.19)
Weighted Average Diluted Shares Outstanding	21.13M	19.83M	25.05M	34.32M	34.36M	32.07M	34.69M	34.69M	51.02M	43.59M	53.38M
Weighted Average Basic & Diluted Shares Outstanding	21.17M	34.25M	34.34M	34.34M	34.39M	34.69M	34.69M	51.10M	53.23M	53.24M	102.66M

This table details how cash moves in and out of Achieve Life Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	0.06	-0.05	5.54	4.01	7.15	19	7.17	-18	-9.23	-2.82	8.18
Net Cash From Operating Activities	-0.35	-0.20	-9.11	-11	-15	-13	-29	-38	-24	-30	-49
Net Cash From Continuing Operating Activities	-0.35	-0.20	-9.11	-11	-15	-14	-29	-38	-24	-30	-49
Net Income / (Loss) Continuing Operations	-0.83	-1.23	-11	-13	-16	-15	-33	-42	-30	-40	-55
Consolidated Net Income / (Loss)	-0.83	-1.23	-11	-13	-16	-15	-33	-42	-30	-40	-55
Depreciation Expense	-	-	0.06	0.06	0.03	0.26	0.25	0.24	0.23	0.23	0.23
Amortization Expense	0.14	0.22	0.22	0.22	0.22	-	-	0.00	0.00	0.02	0.05
Non-Cash Adjustments To Reconcile Net Income	-	-	8.70	0.85	1.21	1.29	2.02	4.51	5.29	6.88	8.76
Changes in Operating Assets and Liabilities, net	0.34	0.81	-7.50	0.93	-0.28	-0.34	1.40	0.04	-0.19	2.92	-3.86
Net Cash From Investing Activities	-2.00	0.00	13	-5.13	5.04	-0.02	0.00	0.00	-0.02	-22	6.11
Net Cash From Continuing Investing Activities	-2.00	0.00	13	-5.13	5.04	-0.02	0.00	0.00	-0.02	-22	6.11
Purchase of Property, Plant & Equipment	-	-	-	-0.05	-0.05	-0.02	0.00	0.00	-0.02	0.00	-0.00
Purchase of Investments	-	-	-	-5.54	-0.03	-	-	0.00	0.00	-48	-25
Sale and/or Maturity of Investments	-	-	-	0.45	5.11	-	-	0.00	0.00	26	31
Other Investing Activities, net	-2.00	-	13	-	-	-	-	-	0.00	0.00	0.00
Net Cash From Financing Activities	2.41	0.15	2.00	20	17	33	37	19	15	49	52
Net Cash From Continuing Financing Activities	2.41	0.15	2.00	20	17	33	37	19	15	49	52
Repayment of Debt	-0.27	-	-	-	-	0.00	0.00	0.00	0.00	-18	5.00
Repurchase of Common Equity	-	-	-	0.00	0.00	-0.05	0.00	0.00	0.00	0.00	0.00
Issuance of Debt	2.68	0.15	-	12	12	0.00	15	0.00	0.00	9.81	0.00
Issuance of Common Equity	-	-	2.01	6.24	0.79	29	21	19	15	56	45
Other Financing Activities, net	-	-	0.01	1.32	4.20	3.23	0.34	-0.02	0.01	0.57	1.39
Effect of Exchange Rate Changes	-	-	-	-	-	0.00	-	0.00	-0.00	0.00	0.00

This table details how cash moves in and out of Achieve Life Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-5.15	-4.37	51	-52	-5.21	3.21	0.26	39	-20	-11	7.36
Net Cash From Operating Activities	-5.14	-4.36	-5.29	-4.92	-10	-9.19	-11	-9.07	-11	-18	-6.93
Net Cash From Continuing Operating Activities	-5.17	-4.36	-5.29	-4.92	-10	-9.19	-11	-9.07	-11	-18	-6.93
Net Income / (Loss) Continuing Operations	-7.11	-5.48	-6.49	-8.46	-13	-12	-13	-13	-14	-15	-10
Consolidated Net Income / (Loss)	-7.11	-5.48	-6.49	-8.46	-13	-12	-13	-13	-14	-15	-10
Depreciation Expense	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.05	0.06	0.06
Amortization Expense	-	-	0.00	-	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Non-Cash Adjustments To Reconcile Net Income	2.59	0.43	1.77	2.03	1.84	1.24	2.23	2.89	2.34	1.30	-0.69
Changes in Operating Assets and Liabilities, net	-0.71	0.63	-0.62	1.45	0.23	1.86	-0.57	0.69	0.70	-4.69	3.85
Net Cash From Investing Activities	-0.02	-0.01	0.00	-47	13	12	11	6.70	-13	0.71	14
Net Cash From Continuing Investing Activities	-0.02	-0.01	0.00	-47	13	12	11	6.70	-13	0.71	14
Purchase of Property, Plant & Equipment	-	-0.01	0.00	-	-	-	0.00	-	-	-0.00	0.00
Purchase of Investments	-	-	0.00	-47	-0.39	-0.93	-3.36	-0.90	-15	-5.09	-1.16
Sale and/or Maturity of Investments	-	-	0.00	-	14	13	15	7.60	2.75	5.80	15
Net Cash From Financing Activities	-	-	56	-0.15	-8.11	0.68	0.00	41	4.04	6.26	0.02
Net Cash From Continuing Financing Activities	-0.03	-	56	-0.15	-8.11	0.68	0.00	41	4.04	6.26	0.02
Repayment of Debt	-	-	-	-	-	-	0.00	-	-	5.00	0.00
Issuance of Debt	-	-	-	-	-	-	0.00	-	-	-	0.00
Issuance of Common Equity	-	-0.03	56	-0.04	0.18	-	0.00	-	3.92	-0.00	0.00
Other Financing Activities, net	-0.03	0.03	-	-	-	0.68	0.00	-	0.12	1.27	0.02
Other Net Changes in Cash	-	-	-	-	-	-	-0.00	0.00	-	-	0.00

This table presents Achieve Life Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	58	3.81	9.89	19	21	40	48	30	19	39	42
Total Current Assets	57	0.02	5.91	16	17	37	45	27	17	36	40
Cash & Equivalents	34	0.02	5.28	9.52	17	36	43	25	16	13	21
Short-Term Investments	21	-	-	5.09	-	-	-	-	0.00	22	15
Prepaid Expenses	1.99	0.00	0.39	0.93	0.67	1.12	1.42	2.45	1.33	2.11	3.49
Other Current Assets	-	-	-	-	-	0.00	0.15	0.11	0.11	0.00	0.00
Plant, Property, & Equipment, net	0.60	0.00	0.06	0.04	0.06	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	0.31	3.79	3.93	3.51	3.69	3.32	2.92	2.64	2.39	2.17	1.90
Goodwill	-	1.03	1.03	1.03	1.03	1.03	1.03	1.03	1.03	1.03	1.03
Intangible Assets	-	2.76	2.53	2.31	2.09	1.86	1.64	1.42	1.20	0.97	0.75
Other Noncurrent Operating Assets	0.04	-	0.31	0.12	0.52	0.43	0.25	0.19	0.16	0.16	0.12
Total Liabilities & Shareholders' Equity	58	3.81	9.89	19	21	40	48	30	19	39	42
Total Liabilities	21	3.20	2.01	3.28	3.03	3.01	19	22	21	18	20
Total Current Liabilities	21	3.07	2.01	3.27	2.87	2.94	4.55	22	21	6.68	9.08
Short-Term Debt	0.05	-	0.03	-	-	-	0.00	16	17	0.00	5.26
Accounts Payable	1.34	0.92	0.21	0.14	0.86	0.33	0.84	1.66	0.62	1.95	0.87
Accrued Expenses	11	2.15	1.32	1.95	0.69	1.04	1.70	2.13	0.63	1.65	0.97
Current Employee Benefit Liabilities	1.27	-	0.46	1.17	1.12	1.47	1.94	1.68	2.31	3.03	1.92
Other Current Liabilities	2.36	-	-	0.01	0.20	0.09	0.07	0.06	0.06	0.06	0.06
Total Noncurrent Liabilities	0.11	0.12	0.00	0.01	0.16	0.08	15	0.07	0.01	11	11
Long-Term Debt	-	-	-	-	-	-	15	0.00	0.00	9.84	11
Other Noncurrent Operating Liabilities	-	-	-	0.01	0.16	0.08	0.00	0.07	0.01	1.22	0.01
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	37	0.61	7.88	16	18	37	28	8.30	-1.45	21	22
Total Preferred & Common Equity	37	0.61	7.88	16	18	37	28	8.30	-1.45	21	22
Preferred Stock	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	37	0.61	7.88	16	18	37	28	8.30	-1.45	21	22
Common Stock	212	2.67	21	41	64	98	122	144	164	226	282
Retained Earnings	-177	-2.06	-13	-25	-46	-60	-94	-136	-166	-206	-260
Accumulated Other Comprehensive Income / (Loss)	2.63	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.01

This table presents Achieve Life Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	24	70	65	48	27	59	52	33
Total Current Assets	22	68	63	46	25	57	50	31
Cash & Equivalents	20	66	15	9.54	13	52	32	28
Short-Term Investments	-	-	47	33	10	3.52	16	1.19
Prepaid Expenses	1.90	1.31	1.21	2.62	1.76	1.51	1.94	1.79
Other Current Assets	0.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	2.44	2.32	2.27	2.39	2.36	2.03	1.99	2.04
Goodwill	1.03	1.03	1.03	1.03	1.03	1.03	1.03	1.03
Intangible Assets	1.25	1.14	1.09	1.03	0.92	0.86	0.81	0.70
Other Noncurrent Operating Assets	0.15	0.15	0.15	0.32	0.41	0.14	0.14	0.31
Total Liabilities & Shareholders' Equity	24	70	65	48	27	59	52	33
Total Liabilities	20	21	23	17	17	17	18	22
Total Current Liabilities	4.08	21	14	6.72	7.13	8.57	9.73	12
Short-Term Debt	0.00	17	8.80	0.00	1.19	2.55	2.65	5.58
Accounts Payable	0.64	0.37	0.55	1.01	1.66	1.22	1.94	0.83
Accrued Expenses	1.68	1.56	2.33	2.64	3.26	3.19	2.65	3.19
Current Employee Benefit Liabilities	1.70	0.86	1.35	2.34	0.96	1.56	2.43	2.18
Other Current Liabilities	0.06	0.63	0.67	0.72	0.06	0.06	0.06	0.05
Total Noncurrent Liabilities	16	0.00	8.80	9.82	9.95	8.69	8.70	11
Long-Term Debt	16	0.00	8.80	9.82	8.66	8.66	8.67	9.32
Other Noncurrent Operating Liabilities	0.02	0.00	0.00	0.00	1.29	0.04	0.02	1.27
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	4.04	49	42	31	10	42	34	11
Total Preferred & Common Equity	4.04	49	42	31	10	42	34	11
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	4.04	49	42	31	10	42	34	11
Common Stock	164	222	223	225	229	273	279	281
Retained Earnings	-160	-172	-181	-193	-218	-231	-246	-270
Accumulated Other Comprehensive Income / (Loss)	0.00	0.00	-0.01	0.08	0.01	0.00	0.01	0.00

This table displays calculated financial ratios and metrics derived from Achieve Life Sciences' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	29,804,273.00	30,020,294.00	11,947,676.00	6,721,103.00	8,352,764.00	3,617,664.00	9,453,542.00	9,710,747.00	21,165,760.00	34,389,946.00	53,233,988.00
DEI Adjusted Shares Outstanding	13,547.00	13,646.00	59,738.00	336,055.00	417,638.00	3,617,664.00	9,453,542.00	9,710,747.00	21,165,760.00	34,389,946.00	53,233,988.00
DEI Earnings Per Adjusted Shares Outstanding	-1,240.20	-90.43	-177.16	-37.75	-39.26	-4.07	-3.51	-4.36	-1.41	-1.16	-1.03
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-33.03%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	35.59%	90.97%	-782.71%	5.96%	-29.70%	10.83%	-126.34%	-23.10%	31.99%	-43.21%	-39.46%
EBIT Growth	35.60%	89.73%	-685.67%	5.84%	-28.83%	10.66%	-124.13%	-22.89%	31.83%	-42.94%	-39.29%
NOPAT Growth	36.36%	90.86%	-286.93%	-93.20%	-28.99%	10.76%	-124.37%	-23.29%	31.92%	-42.88%	-38.27%
Net Income Growth	35.97%	92.66%	-757.62%	-19.88%	-29.23%	10.16%	-125.06%	-27.74%	29.60%	-33.58%	-37.21%
EPS Growth	55.86%	92.66%	-757.62%	-19.88%	-29.23%	86.37%	24.72%	1.96%	62.50%	17.33%	-0.81%
Operating Cash Flow Growth	97.98%	42.29%	-4,408.42%	-16.65%	-43.24%	11.45%	-118.49%	-27.61%	34.84%	-21.61%	-66.16%
Free Cash Flow Firm Growth	-55.47%	-137.82%	67.45%	-21.41%	-51.38%	11.36%	-107.95%	-30.22%	29.00%	-19.59%	-81.95%
Invested Capital Growth	-37.40%	103.33%	294.96%	-51.15%	16.38%	7.26%	-104.19%	-561.67%	149.37%	-1,948.98%	143.05%
Revenue Q/Q Growth	2.09%	-100.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	18.66%	88.22%	-2,413.72%	1.76%	4.23%	-9.82%	-7.90%	-9.89%	17.63%	-24.37%	-4.16%
EBIT Q/Q Growth	18.91%	86.49%	-2,466.73%	0.24%	2.92%	-11.49%	-7.83%	-9.83%	17.53%	-24.23%	-4.13%
NOPAT Q/Q Growth	14.53%	88.33%	-199.77%	0.56%	2.94%	-11.42%	-7.80%	-10.11%	17.64%	-24.64%	-3.33%
Net Income Q/Q Growth	19.07%	90.20%	-479.73%	0.81%	2.63%	-11.59%	-7.90%	-10.66%	16.18%	-20.90%	-4.40%
EPS Q/Q Growth	12.33%	90.20%	-479.73%	0.81%	2.63%	-35.16%	-25.54%	-1.27%	26.47%	-12.73%	10.07%
Operating Cash Flow Q/Q Growth	93.47%	90.26%	-64.21%	0.77%	0.83%	6.48%	-10.25%	-18.72%	21.69%	-19.34%	-21.60%
Free Cash Flow Firm Q/Q Growth	-1,982.71%	32.95%	-7.21%	-2.49%	-1.01%	11.55%	-10.32%	-21.87%	20.84%	-18.23%	-22.10%
Invested Capital Q/Q Growth	34.38%	107.27%	-3.53%	15.38%	86.59%	-55.66%	-104.32%	71.44%	-37.58%	-111.93%	149.09%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-92.40%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-103.27%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-93.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-92.52%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	71.00%	77.62%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	99.30%	100.00%	99.85%	98.67%	98.97%	99.53%	99.95%	103.90%	107.30%	100.27%	98.78%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-47.00%	-6.49%	-249.33%	-107.15%	-96.86%	-53.24%	-101.49%	-233.04%	-869.88%	-409.51%	-257.67%
Cash Return on Invested Capital (CROIC)	0.00%	-3,303.50%	-434.46%	-444.09%	-946.67%	-752.76%	0.00%	0.00%	-10,223.27%	0.00%	-2,794.87%
Operating Return on Assets (OROA)	-29.55%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-29.35%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-47.00%	-6.49%	-249.33%	-107.15%	-96.86%	-53.24%	-101.49%	-233.04%	-869.88%	-409.51%	-257.67%
Return on Equity Simple (ROE_SIMPLE)	-44.87%	-202.30%	-134.32%	-80.29%	-90.83%	-39.51%	-118.22%	-510.06%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-13	-1.20	-4.64	-8.97	-12	-10	-23	-29	-19	-28	-38
NOPAT Margin	-72.29%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-7.18%	-0.12%	-214.31%	-36.84%	-30.77%	-16.76%	-31.23%	-74.94%	-293.95%	-105.28%	-72.98%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-117.17%	-123.52%	-90.39%	-101.19%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	65.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	138.26%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	203.27%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-17	-1.74	-14	-13	-17	-15	-33	-41	-28	-40	-55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-17	-1.52	-13	-13	-16	-15	-33	-41	-28	-39	-55
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.96	24.60	2.04	0.51	0.25	0.79	2.62	2.87	0.00	5.79	12.30
Price to Tangible Book Value (P/TBV)	0.96	0.00	3.72	0.65	0.30	0.85	2.90	4.07	0.00	6.41	13.41
Price to Revenue (P/Rev)	1.99	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	25.20	4.50	0.00	0.00	0.00	0.00	0.00	453.30	0.00	156.80
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.53	1.94	-11.87	0.47	0.76
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.53	0.00	0.00	0.47	0.52
Financial Leverage	-1.43	-1.45	-0.65	-0.85	-0.93	-0.95	-0.98	-1.01	-1.03	-1.18	-1.05
Leverage Ratio	1.60	1.63	1.61	1.22	1.19	1.11	1.34	2.13	7.20	2.98	1.90
Compound Leverage Factor	1.59	1.63	1.61	1.21	1.17	1.10	1.34	2.22	7.72	2.99	1.87
Debt to Total Capital	0.42%	0.00%	0.34%	0.00%	0.00%	0.00%	34.73%	65.94%	109.20%	32.00%	43.32%
Short-Term Debt to Total Capital	0.14%	0.00%	0.34%	0.00%	0.00%	0.00%	0.00%	65.94%	109.20%	0.00%	13.86%
Long-Term Debt to Total Capital	0.28%	0.00%	0.00%	0.00%	0.00%	0.00%	34.73%	0.00%	0.00%	32.00%	29.46%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.58%	100.00%	99.66%	100.00%	100.00%	100.00%	65.27%	34.07%	-9.20%	68.00%	56.68%
Debt to EBITDA	-0.01	0.00	0.00	0.00	0.00	0.00	-0.45	-0.40	-0.62	-0.25	-0.30
Net Debt to EBITDA	3.28	0.00	0.41	0.00	0.00	0.00	0.85	0.21	-0.06	0.62	0.36
Long-Term Debt to EBITDA	-0.01	0.00	0.00	0.00	0.00	0.00	-0.45	0.00	0.00	-0.25	-0.20
Debt to NOPAT	-0.01	0.00	-0.01	0.00	0.00	0.00	-0.64	-0.56	-0.88	-0.35	-0.43
Net Debt to NOPAT	4.19	0.00	1.18	0.00	0.00	0.00	1.21	0.30	-0.08	0.88	0.52
Long-Term Debt to NOPAT	-0.01	0.00	0.00	0.00	0.00	0.00	-0.64	0.00	0.00	-0.35	-0.29
Altman Z-Score	-3.10	-0.41	-1.10	-1.83	-3.93	3.54	-1.78	-9.95	-14.44	-5.82	-4.37
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.77	0.01	2.93	4.75	6.04	12.60	9.80	1.27	0.82	5.46	4.39
Quick Ratio	2.68	0.00	2.63	4.47	5.81	12.22	9.46	1.15	0.75	5.14	4.01
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-8.27	-20	-6.40	-7.77	-12	-10	-22	-28	-20	-24	-44
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	-29,508.33%	-28,709.43%	-79,258.82%	0.00%	0.00%	-116,566.67%	0.00%	-1,236,625.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-15.78	-7.02	-9.73	-53.24
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-21.00	-8.58	-12.09	-60.40
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-21.00	-8.59	-12.09	-60.40
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	6.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	42.28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	57.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	57.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-18	0.60	2.35	1.15	1.34	1.43	-0.06	-0.40	0.20	-3.62	1.56
Invested Capital Turnover	-1.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-4.86	18	1.76	-1.20	0.19	0.10	-1.49	-0.34	0.59	-3.82	5.18
Enterprise Value (EV)	-19	15	11	-6.47	-12	-6.55	45	15	89	97	245
Market Capitalization	36	15	16	8.13	4.43	29	74	24	87	121	265
Book Value per Share	$1.26	$0.02	$0.66	$2.35	$2.16	$10.31	$2.97	$0.86	($0.07)	$0.61	$0.40
Tangible Book Value per Share	$1.26	($0.11)	$0.36	$1.85	$1.79	$9.51	$2.68	$0.60	($0.17)	$0.55	$0.37
Total Capital	38	0.61	7.91	16	18	37	43	24	16	31	38
Total Debt	0.16	0.00	0.03	0.00	0.00	0.00	15	16	17	9.84	16
Total Long-Term Debt	0.11	0.00	0.00	0.00	0.00	0.00	15	0.00	0.00	9.84	11
Net Debt	-55	-0.02	-5.48	-15	-17	-36	-28	-8.70	1.64	-25	-20
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.04	0.05	0.02	0.00	0.00	0.02	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-19	-3.07	-1.58	-2.34	-2.20	-1.81	-2.98	-2.97	-2.19	-4.58	-0.34
Debt-free Net Working Capital (DFNWC)	37	-3.06	3.92	12	14	34	40	22	13	30	36
Net Working Capital (NWC)	37	-3.06	3.90	12	14	34	40	5.73	-3.83	30	31
Net Nonoperating Expense (NNE)	3.67	0.03	5.94	3.72	4.83	4.41	9.99	14	10	12	16
Net Nonoperating Obligations (NNO)	-55	-0.02	-5.53	-15	-17	-36	-28	-8.70	1.64	-25	-20
Total Depreciation and Amortization (D&A)	0.14	0.22	0.28	0.28	0.25	0.26	0.25	0.24	0.23	0.25	0.28
Debt-free, Cash-free Net Working Capital to Revenue	-101.87%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	202.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	201.73%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1,408.00)	($1,474.00)	($442.00)	($72.20)	($39.80)	$0.00	$0.00	($4.00)	($1.50)	($1.24)	($1.25)
Adjusted Weighted Average Basic Shares Outstanding	13.55K	13.68K	63.74K	336.06K	1.57M	0.00	0.00	10.59M	19.83M	32.07M	43.59M
Adjusted Diluted Earnings per Share	($1,408.00)	($1,474.00)	($442.00)	($72.20)	($39.80)	$0.00	$0.00	($4.00)	($1.50)	($1.24)	($1.25)
Adjusted Weighted Average Diluted Shares Outstanding	13.55K	13.68K	63.74K	336.06K	1.57M	0.00	0.00	10.59M	19.83M	32.07M	43.59M
Adjusted Basic & Diluted Earnings per Share	($1,408.00)	($1,474.00)	($442.00)	($72.20)	($39.80)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	11.89K	13.61K	23.97K	175.51K	412.32K	0.00	0.00	17.93M	34.25M	34.69M	53.24M
Normalized Net Operating Profit after Tax (NOPAT)	-13	-1.20	-4.64	-8.97	-12	-10	-23	-29	-19	-27	-38
Normalized NOPAT Margin	-72.29%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-92.52%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-22.78	-9.74	-16.13	-67.55
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-15.96	-6.82	-11.28	-46.91
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-22.78	-9.75	-16.13	-67.56
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-15.96	-6.82	-11.28	-46.91
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-0.33%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Achieve Life Sciences' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	21,105,760.00	21,165,760.00	34,251,911.00	34,341,303.00	34,341,303.00	34,389,946.00	34,685,072.00	34,685,072.00	51,104,968.00	53,233,988.00	53,239,988.00
DEI Adjusted Shares Outstanding	21,105,760.00	21,165,760.00	34,251,911.00	34,341,303.00	34,341,303.00	34,389,946.00	34,685,072.00	34,685,072.00	51,104,968.00	53,233,988.00	53,239,988.00
DEI Earnings Per Adjusted Shares Outstanding	-0.34	-0.26	-0.19	-0.25	-0.36	-0.36	-0.37	-0.37	-0.28	-0.28	-0.19
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	48.22%	54.93%	29.70%	-10.02%	-90.94%	-159.77%	-115.09%	-50.01%	-18.17%	-17.47%	21.46%
EBIT Growth	47.99%	54.67%	29.51%	-9.97%	-90.26%	-158.22%	-114.32%	-49.81%	-18.08%	-17.34%	21.39%
NOPAT Growth	48.00%	54.76%	29.66%	-9.29%	-89.68%	-159.65%	-113.69%	-50.16%	-18.71%	-13.86%	18.85%
Net Income Growth	45.65%	51.25%	27.78%	-2.69%	-76.03%	-125.71%	-97.52%	-50.31%	-15.42%	-18.62%	20.73%
EPS Growth	74.81%	70.13%	48.00%	41.86%	-5.88%	-60.87%	-42.31%	-48.00%	22.22%	37.84%	48.65%
Operating Cash Flow Growth	54.58%	60.84%	36.31%	26.29%	-101.95%	-110.56%	-109.68%	-84.29%	-9.25%	-95.64%	37.48%
Free Cash Flow Firm Growth	-3.87%	44.50%	31.71%	36.68%	-6.31%	-26.74%	-38.54%	-88.10%	-32.65%	-200.39%	-18.16%
Invested Capital Growth	122.59%	149.37%	-33.67%	-495.54%	-644.59%	-1,948.98%	-1,665.33%	-77.96%	-85.85%	143.05%	-18.46%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	14.79%	25.89%	-23.80%	-40.74%	-47.87%	-0.83%	-2.51%	1.85%	-16.49%	-0.23%	31.47%
EBIT Q/Q Growth	14.65%	25.68%	-23.52%	-40.35%	-47.66%	-0.87%	-2.52%	1.89%	-16.38%	-0.24%	31.32%
NOPAT Q/Q Growth	14.80%	25.23%	-22.79%	-39.72%	-47.86%	-2.35%	-1.06%	1.81%	-16.89%	1.82%	27.98%
Net Income Q/Q Growth	13.73%	22.96%	-18.59%	-30.29%	-47.88%	1.21%	-3.78%	0.85%	-13.55%	-1.53%	30.65%
EPS Q/Q Growth	20.93%	32.35%	-13.04%	3.85%	-44.00%	-2.78%	0.00%	0.00%	24.32%	17.86%	17.39%
Operating Cash Flow Q/Q Growth	23.07%	15.03%	-21.17%	6.94%	-110.77%	11.41%	-20.67%	18.21%	-24.94%	-58.65%	61.44%
Free Cash Flow Firm Q/Q Growth	3.17%	36.03%	-2.23%	0.00%	-62.57%	23.74%	-11.75%	-35.77%	-14.64%	-72.69%	56.04%
Invested Capital Q/Q Growth	-12.53%	-37.58%	1.53%	-813.57%	-20.42%	-111.93%	14.05%	18.88%	-25.76%	149.09%	-336.54%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	107.88%	111.82%	107.36%	99.66%	99.81%	97.75%	98.94%	99.99%	97.55%	98.81%	99.77%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-1,399.88%	-869.88%	-109.49%	-105.95%	-186.03%	-409.51%	-154.55%	-120.11%	-161.08%	-257.67%	-496.15%
Cash Return on Invested Capital (CROIC)	-8,061.21%	-10,223.27%	-7,039.20%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,794.87%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-1,399.88%	-869.88%	-109.49%	-105.95%	-186.03%	-409.51%	-154.55%	-120.11%	-161.08%	-257.67%	-496.15%
Return on Equity Simple (ROE_SIMPLE)	-880.91%	0.00%	-55.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-4.60	-3.44	-4.22	-5.90	-8.73	-8.93	-9.03	-8.86	-10	-10	-7.32
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-81.44%	-57.72%	-9.19%	-9.65%	-20.57%	-29.97%	-12.13%	-8.77%	-11.68%	-20.20%	-20.49%
Return On Investment Capital (ROIC_SIMPLE)	-	-21.85%	-6.34%	-9.85%	-21.18%	-29.06%	-44.84%	-16.76%	-23.05%	-26.79%	-28.63%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-6.59	-4.90	-6.05	-8.49	-13	-13	-13	-13	-15	-15	-10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.53	-4.84	-5.99	-8.43	-12	-13	-13	-13	-15	-15	-10
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	22.48	0.00	3.15	3.82	5.19	5.79	9.01	1.88	4.79	12.30	14.66
Price to Tangible Book Value (P/TBV)	51.80	0.00	3.29	4.02	5.55	6.41	11.12	1.97	5.07	13.41	17.49
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	277.17	453.30	534.76	0.00	0.00	0.00	0.00	0.00	0.00	156.80	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	4.01	-11.87	0.35	0.42	0.31	0.47	0.96	0.27	0.34	0.76	1.40
Long-Term Debt to Equity	4.01	0.00	0.00	0.21	0.31	0.47	0.84	0.21	0.26	0.52	0.87
Financial Leverage	-1.21	-1.03	-0.99	-1.02	-1.04	-1.18	-1.05	-1.05	-1.08	-1.05	-1.32
Leverage Ratio	9.46	7.20	1.82	1.80	2.04	2.98	1.63	1.47	1.54	1.90	2.89
Compound Leverage Factor	10.20	8.05	1.95	1.80	2.04	2.91	1.61	1.47	1.50	1.87	2.88
Debt to Total Capital	80.04%	109.20%	25.74%	29.40%	23.84%	32.00%	48.94%	21.19%	25.19%	43.32%	58.25%
Short-Term Debt to Total Capital	0.00%	109.20%	25.74%	14.70%	0.00%	0.00%	5.93%	4.81%	5.89%	13.86%	21.81%
Long-Term Debt to Total Capital	80.04%	0.00%	0.00%	14.70%	23.84%	32.00%	43.01%	16.37%	19.30%	29.46%	36.44%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	19.96%	-9.20%	74.26%	70.60%	76.16%	68.00%	51.06%	78.81%	74.81%	56.68%	41.75%
Debt to EBITDA	-0.48	-0.62	-0.68	-0.68	-0.31	-0.25	-0.21	-0.22	-0.21	-0.30	-0.29
Net Debt to EBITDA	0.11	-0.06	1.97	1.69	1.04	0.62	0.29	0.87	0.70	0.36	0.27
Long-Term Debt to EBITDA	-0.48	0.00	0.00	-0.34	-0.31	-0.25	-0.19	-0.17	-0.16	-0.20	-0.18
Debt to NOPAT	-0.69	-0.88	-0.97	-0.97	-0.44	-0.35	-0.30	-0.32	-0.30	-0.43	-0.41
Net Debt to NOPAT	0.16	-0.08	2.79	2.41	1.48	0.88	0.41	1.24	0.99	0.52	0.39
Long-Term Debt to NOPAT	-0.69	0.00	0.00	-0.48	-0.44	-0.35	-0.27	-0.24	-0.23	-0.29	-0.25
Altman Z-Score	-6.55	-10.54	1.62	0.87	0.37	-3.51	-8.70	-2.49	-1.37	-1.17	-7.57
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.36	0.82	3.29	4.56	6.78	5.46	3.51	6.64	5.14	4.39	2.62
Quick Ratio	4.88	0.75	3.23	4.47	6.39	5.14	3.26	6.46	4.94	4.01	2.47
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6.30	-4.03	-4.12	-4.12	-6.70	-5.11	-5.71	-7.76	-8.89	-15	-6.75
Operating Cash Flow to CapEx	0.00%	-72,733.33%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-449,425.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-8.07	-5.12	-5.07	-5.13	-10.33	-25.95	-30.87	-40.60	-46.31	-61.17	-24.63
Operating Cash Flow to Interest Expense	-6.58	-5.55	-6.50	-6.12	-15.98	-46.64	-59.94	-47.48	-59.02	-71.62	-25.30
Operating Cash Flow Less CapEx to Interest Expense	-6.58	-5.55	-6.50	-6.12	-15.98	-46.64	-59.94	-47.48	-59.02	-71.64	-25.30
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.31	0.20	0.20	-1.42	-1.71	-3.62	-3.12	-2.53	-3.18	1.56	-3.69
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	1.70	0.59	-0.10	-1.78	-2.02	-3.82	-3.31	-1.11	-1.47	5.18	-0.58
Enterprise Value (EV)	87	89	106	118	130	97	79	34	124	245	142
Market Capitalization	91	87	156	161	163	121	93	78	161	265	157
Book Value per Share	$0.19	($0.07)	$1.44	$1.23	$0.91	$0.61	$0.30	$1.20	$0.66	$0.40	$0.20
Tangible Book Value per Share	$0.08	($0.17)	$1.38	$1.17	$0.85	$0.55	$0.24	$1.15	$0.62	$0.37	$0.17
Total Capital	20	16	67	60	41	31	20	53	45	38	26
Total Debt	16	17	17	18	9.82	9.84	9.85	11	11	16	15
Total Long-Term Debt	16	0.00	0.00	8.80	9.82	9.84	8.66	8.66	8.67	11	9.32
Net Debt	-3.72	1.64	-49	-44	-33	-25	-13	-44	-37	-20	-14
Capital Expenditures (CapEx)	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.10	-2.19	-2.12	-3.69	-4.10	-4.58	-4.18	-4.52	-5.14	-0.34	-4.46
Debt-free Net Working Capital (DFNWC)	18	13	64	58	39	30	19	51	43	36	25
Net Working Capital (NWC)	18	-3.83	47	49	39	30	18	48	40	31	19
Net Nonoperating Expense (NNE)	2.51	2.04	2.27	2.56	3.79	3.43	3.80	3.86	4.08	4.49	2.84
Net Nonoperating Obligations (NNO)	-3.72	1.64	-49	-44	-33	-25	-13	-44	-37	-20	-14
Total Depreciation and Amortization (D&A)	0.06	0.06	0.06	0.06	0.07	0.07	0.08	0.07	0.07	0.07	0.07
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.34)	($0.23)	($0.26)	($0.25)	($0.36)	($0.37)	($0.37)	($0.37)	($0.28)	($0.23)	($0.19)
Adjusted Weighted Average Basic Shares Outstanding	21.13M	19.83M	25.05M	34.32M	34.36M	32.07M	34.69M	34.69M	51.02M	43.59M	53.38M
Adjusted Diluted Earnings per Share	($0.34)	($0.23)	($0.26)	($0.25)	($0.36)	($0.37)	($0.37)	($0.37)	($0.28)	($0.23)	($0.19)
Adjusted Weighted Average Diluted Shares Outstanding	21.13M	19.83M	25.05M	34.32M	34.36M	32.07M	34.69M	34.69M	51.02M	43.59M	53.38M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	21.17M	34.25M	34.34M	34.34M	34.39M	34.69M	34.69M	51.10M	53.23M	53.24M	102.66M
Normalized Net Operating Profit after Tax (NOPAT)	-4.60	-3.07	-4.19	-5.90	-8.73	-8.93	-9.03	-8.79	-10	-10	-7.32
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-8.44	-6.22	-7.44	-10.56	-19.32	-64.19	-70.08	-66.59	-77.10	-59.12	-37.19
NOPAT to Interest Expense	-5.89	-4.37	-5.20	-7.34	-13.45	-45.34	-48.79	-46.40	-53.95	-40.52	-26.73
EBIT Less CapEx to Interest Expense	-8.44	-6.23	-7.44	-10.56	-19.32	-64.19	-70.08	-66.59	-77.10	-59.13	-37.19
NOPAT Less CapEx to Interest Expense	-5.89	-4.38	-5.20	-7.34	-13.45	-45.34	-48.79	-46.40	-53.95	-40.53	-26.73
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Achieve Life Sciences (NASDAQ: ACHV) remains a development-stage biotech with no revenue, and its recent financial statements show continued operating losses, though its cash position improved sharply in Q1 2026.

For the quarter ended March 31, 2026, ACHV reported zero revenue and a net loss of $10.2 million, compared with a net loss of $14.7 million in Q4 2025 and $12.7 million in Q2 2025. Operating expenses were $10.5 million in the quarter, down from $14.5 million in Q4 2025, reflecting somewhat lower spending on SG&A and R&D.

One of the biggest positives was the company’s cash build. Cash and equivalents rose to $28.1 million from $13.0 million at the end of Q1 2025, while short-term investments were $1.2 million. Total current assets were $31.1 million, and total assets were $33.1 million. The increase in cash came largely from investing activity and a strong quarter in working-capital changes, even though core operations still burned cash.

That said, ACHV continues to rely on external funding and balance-sheet leverage. Total liabilities were $22.4 million, including $5.6 million of short-term debt and $9.3 million of long-term debt. Equity was only $10.7 million, meaning debt remains a meaningful part of the capital structure.

Over the longer trend, the company’s quarterly losses have generally stayed in the $10 million to $15 million range, while operating cash burn has been substantial. However, the recent quarter showed some improvement versus late 2025, with lower operating losses and a higher cash balance.

Cash and equivalents increased to $28.1 million in Q1 2026 from $13.0 million at Q1 2025, improving near-term liquidity.
Operating loss improved to $10.5 million from $14.5 million in Q4 2025, suggesting some expense moderation.
Quarterly net loss narrowed versus Q4 2025, falling to $10.2 million from $14.7 million.
Investment activity contributed positive cash in Q1 2026, helping offset operating burn.
Revenue remained at zero, so the business is still entirely dependent on financing and clinical progress.
R&D spending remained significant at $3.3 million, which is typical for a biotech but still contributes to losses.
Short-term investments were modest at $1.2 million, so most liquidity sits in cash rather than a larger investment portfolio.
Operating cash flow was negative at $6.9 million in Q1 2026, showing the core business still consumes cash.
Total liabilities remain elevated at $22.4 million relative to $10.7 million in equity.
ACHV has no product revenue and continues to post recurring losses, increasing reliance on future financing.

Bottom line: ACHV’s latest quarter was not profitable, but it did show a better liquidity picture and slightly better operating discipline. For retail investors, the key question remains whether the company can advance its pipeline without needing too much additional dilution or debt.

07/21/26 06:22 PM ETAI Generated. May Contain Errors.

Achieve Life Sciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Achieve Life Sciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Achieve Life Sciences' net income appears to be on an upward trend, with a most recent value of -$54.65 million in 2025, rising from -$16.80 million in 2015. The previous period was -$39.83 million in 2024. View Achieve Life Sciences' forecast to see where analysts expect Achieve Life Sciences to go next.

Achieve Life Sciences' total operating income in 2025 was -$54.88 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $54.88 million

Over the last 10 years, Achieve Life Sciences' total revenue changed from $18.16 million in 2015 to $0.00 in 2025, a change of -100.0%.

Achieve Life Sciences' total liabilities were at $20.27 million at the end of 2025, a 14.3% increase from 2024, and a 2.4% decrease since 2015.

In the past 10 years, Achieve Life Sciences' cash and equivalents has ranged from $15 thousand in 2016 to $43.02 million in 2021, and is currently $20.93 million as of their latest financial filing in 2025.

Over the last 10 years, Achieve Life Sciences' book value per share changed from 1.26 in 2015 to 0.40 in 2025, a change of -67.8%.

Related Companies

Financial statements for NASDAQ:ACHV last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Achieve Life Sciences (ACHV) Financials

Financials Breakdown Chart

Key Financial Trends

Achieve Life Sciences Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Achieve Life Sciences (ACHV) Financials

Annual Income Statements for Achieve Life Sciences

Quarterly Income Statements for Achieve Life Sciences

Annual Cash Flow Statements for Achieve Life Sciences

Quarterly Cash Flow Statements for Achieve Life Sciences

Annual Balance Sheets for Achieve Life Sciences

Quarterly Balance Sheets for Achieve Life Sciences

Annual Metrics And Ratios for Achieve Life Sciences

Quarterly Metrics And Ratios for Achieve Life Sciences

Financials Breakdown Chart

Key Financial Trends

Achieve Life Sciences Financials - Frequently Asked Questions

When does Achieve Life Sciences' fiscal year end?

How has Achieve Life Sciences' net income changed over the last 10 years?

What is Achieve Life Sciences' operating income?

How has Achieve Life Sciences' revenue changed over the last 10 years?

How much debt does Achieve Life Sciences have?

How much cash does Achieve Life Sciences have?

How has Achieve Life Sciences' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools